

SCHEDULING STATUS: S4**1. NAME OF THE MEDICINAL PRODUCT**

BETAFERON: Recombinant interferon beta-1b 0.250 mg/ml (8.0 million IU), powder and solvent for solution for injection

Diluent for BETAFERON: One vial contains 2 ml sterile sodium chloride solution 0,54 % w/v (10,8 mg sodium chloride per 2 ml) OR
1 prefilled syringe contains 1,2 ml sterile sodium chloride solution 0,54 % w/v (6,48 mg sodium chloride per 1,2 ml).

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Recombinant interferon beta-1b* 0.25 mg (8.0 million IU) per ml when reconstituted.
BETAFERON contains 300 microgram (9.6 million IU) of recombinant interferon beta-1b per vial.
Contains sugar: Mannitol
1 ml solution for injection contains 5.4 mg sodium chloride.
For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Lyophilised cake and solvent for solution for injection.

Lyophilised cake for injection: Sterile white to off-white powder.
Solvent for solution for injection: clear, colourless liquid

4. CLINICAL PARTICULARS**4.1 Therapeutic indications**

BETAFERON is indicated for the treatment of

1. Patients with a single clinical event suggestive of multiple sclerosis (“Clinically Isolated Syndrome” or CIS, patients had a first demyelinating event together with at least two clinically silent brain MR-lesions) to delay progression to definite multiple sclerosis and to delay the progression of sustained neurological disability.
2. Ambulatory patients with relapsing-remitting multiple sclerosis characterised by at least 2 attacks of neurologic dysfunction over a two-year period followed by complete or incomplete recovery.
3. Secondary progressive multiple sclerosis.

4.2 Posology and method of administration

The treatment with BETAFERON should be initiated under the supervision of a medical practitioner experienced in the treatment of the disease.

Method of administration

For subcutaneous injection.

Posology

Adults

Treatment with BETAIFERON should be initiated under the supervision of a medical practitioner experienced in the treatment of the disease.

The recommended dose of BETAIFERON is 8 million IU (0,25 mg), contained in 1 ml of the reconstituted solution to be injected subcutaneously every other day.

Generally, dose titration is recommended at the start of treatment. For this purpose, a special titration pack is available (see “Presentation” for details of the titration pack).

Patients should be started at 0,0625 mg (0,25 ml) subcutaneously every other day and increased slowly to a dose of 0,25 mg (1,0 ml) every other day. The titration period may be adjusted according to individual tolerability.

In the study in patients with multiple sclerosis with a single clinical event, dosage was increased as shown in Table 1.

Table 1: Schedule for dose titration*

treatment day	dose	volume
1, 3, 5	0.0625 mg	0.25 ml
7, 9, 11	0.125 mg	0.5 ml
13, 15, 17	0.1875 mg	0.75 ml
19, 21, 23 et seq.	0.250 mg	1.0 ml

* Titration scheme as used in the study in patients with multiple sclerosis with a single clinical event suggestive of multiple sclerosis. The titration period may be modified according to individual tolerability.

Duration of treatment:

It is not known for how long the patient should be treated. Efficacy for a period of up to 3 years of treatment has been demonstrated in a controlled clinical trial. There are follow-up data under controlled clinical trial conditions for patients with relapsing-remitting multiple sclerosis for up to 5 years and for patients with secondary progressive multiple sclerosis for up to 3 years.

For relapsing-remitting multiple sclerosis, the available data for up to 5 years suggest sustained treatment efficacy of BETAIFERON over the whole time period.

For secondary progressive multiple sclerosis efficacy for a period of two years with limited data for a period of up to 3 years of treatment has been demonstrated under controlled clinical trial conditions.

In patients with a single clinical event suggestive of multiple sclerosis, efficacy has been demonstrated over a period of 5 years.

Children and adolescents:

Efficacy and safety of BETAIFERON were not investigated systematically in children and adolescents of less than 18 years of age.

There is only limited information on the use of BETAIFERON in children under 18 years of age and, therefore, BETAIFERON should not be administered to this age group.

Instructions for use/handling:

BETAIFERON vials and solvent vials:

- Reconstitution

To reconstitute lyophilised interferon beta-1b for injection use a sterile syringe and needle to inject 1,2 ml of the supplied DILUENT FOR BETAIFERON (sodium chloride solution 5,4 mg/ml (0,54 % w/v)) into the BETAIFERON vial. Dissolve the powder completely without shaking.

- Inspection prior to use and preparation of the syringe

Do not use cracked vials. Inspect the reconstituted product visually before use. The reconstituted product is colourless to light yellow and slightly opalescent to opalescent. Discard the product before use if it contains particulate matter or is discoloured. After reconstitution draw 1,0 ml from the vial into the syringe for the administration of 0,25 mg BETAIFERON.

- Disposal

Discard the product before use if it contains particulate matter or is discoloured. Discard any unused solution for injection.

BETAIFERON vials and prefilled solvent syringes (no vial adapter) (1,2 ml syringe containing 1,2 ml solvent):

- Reconstitution

To reconstitute lyophilised interferon beta-1b for injection use the provided prefilled syringe with solvent and a needle to inject the 1,2 ml DILUENT FOR BETAIFERON (sodium chloride solution 5,4 mg/ml (0,54 % w/v)) into the BETAIFERON vial. Dissolve the powder completely without shaking.

- Inspection prior to use and preparation of the syringe

Do not use cracked vials. Inspect the reconstituted product visually before use. The reconstituted product is colourless to light yellow and slightly opalescent to opalescent. Discard the product before use if it contains particulate matter or is discoloured. After reconstitution draw 1,0 ml from the vial into the syringe for the administration of 0,25 mg BETAIFERON.

- Disposal

Discard the product before use if it contains particulate matter or is discoloured. Discard any unused solution for injection.

BETAIFERON vials and prefilled solvent syringes with vial adapter with attached needle (2,25 ml syringe containing 1,2 ml solvent):

- Reconstitution

To reconstitute lyophilised interferon beta-1b for injection connect the vial adapter with attached needle on the vial. Connect the prefilled syringe with solvent to the vial adapter and inject the 1,2 ml DILUENT FOR BETAIFERON (sodium chloride solution 5,4 mg/ml (0,54 % w/v)) into the BETAIFERON vial. Dissolve the powder completely without shaking.

- Inspection prior to use and preparation of the syringe

Do not use cracked vials. Inspect the reconstituted product visually before use. The reconstituted product is colourless to light yellow and slightly opalescent to opalescent. Discard the product before use if it contains particulate matter or is discoloured. After reconstitution draw all the liquid (1,2 ml) back into the syringe. Adjust volume to desired dose, e.g. 1 ml by injecting superfluous solution into the vial. Remove the vial from the vial adapter.

- Disposal

Discard the product before use if it contains particulate matter or is discoloured. Discard any unused solution for injection.

The reconstituted solution contains 8 million IU (0,25 mg) of interferon beta-1b per ml.

For dose titration at the start of treatment draw the respective volume as given in Table 1 – Schedule for dose titration, above.

Incompatibilities:

In the absence of compatibility studies, BETAFERON should not be mixed with other medicinal products.

Treatment should start as soon as the definite diagnosis of relapsing-remitting multiple sclerosis has been made and the patient has had at least two exacerbations. The treating physician should inform the patient of the possible risk and benefit of a treatment with BETAFERON and decide with him/her whether he/she would be willing to accept possible side effects and inconveniences that might be related to the treatment with BETAFERON.

4.3 Contraindications

Patients with a history of hypersensitivity, such as bronchospasm, anaphylaxis and urticaria; to natural or recombinant interferon beta or human albumin or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use*Immune system disorders*

The administration of cytokines to patients with a pre-existing monoclonal gammopathy has been associated with the development of systemic capillary leak syndrome with shock-like symptoms and fatal outcome.

Gastrointestinal disorders:

Cases of pancreatitis were observed with BETAFERON use, frequently associated with hypertriglyceridaemia.

Nervous system disorders :

Patients to be treated with BETAFERON should be informed that depressive disorders and suicidal ideation may be a side effect of the treatment and should report these symptoms immediately to the prescribing medical practitioner. In rare cases these symptoms may result in a suicide attempt. Patients exhibiting depression and suicidal ideation should be monitored closely and cessation of therapy should be considered.

BETAFERON should be administered with caution to patients with previous or current depressive disorders or suicidal ideation.

BETAFERON contains human albumin. Based on effective donor screening and product manufacturing processes, it carries a remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeld-Jacob disease (CJD) is also considered remote. No cases of transmission of viral disease or CJD have ever been identified for albumin.

BETAFERON should be administered with caution to patients with a history of seizures.

Investigations/immunogenicity:

There is a potential for immunogenicity (see section 4.8). The decision to continue or discontinue treatment should be based on all aspects of the patient's disease status rather than on neutralising activity status alone.

Hepato-biliary disorders:

Elevations of serum transaminases, in most cases asymptomatic, mild and transient, occurred very commonly in patients treated with BETAIFERON during clinical trials. Cases of severe hepatic injury, including hepatic failure, have been reported. The most severe events often occurred in patients exposed to other medicines or substances known to be associated with hepatotoxicity or in the presence of comorbid medical conditions (e.g. metastasising malignant disease, severe infection and sepsis, alcohol abuse).

Patients should be monitored for signs of hepatic injury. The occurrence of elevations in serum transaminases should lead to close monitoring and investigation. Withdrawal of BETAIFERON should be considered if the levels significantly increase or if they are associated with clinical symptoms such as jaundice.

In the absence of clinical evidence for liver damage and after normalisation of liver enzymes, a reintroduction of therapy could be considered with appropriate follow-up of hepatic functions.

Cardiac disorders:

BETAIFERON should be used with caution in patients with pre-existing cardiac disease such as congestive heart failure, coronary artery disease or dysrhythmias. While there is no evidence of a direct cardiotoxic potential for BETAIFERON, these patients should be monitored for worsening of their cardiac condition. This applies particularly during initiation of treatment with BETAIFERON, where flu-like symptoms, commonly associated with beta interferons, exert cardiac stress through fever, chills and tachycardia. This may aggravate cardiac symptoms in patients with pre-existing significant cardiac disease.

During the postmarketing period, reports have been received of worsening of cardiac status in patients with pre-existing significant cardiac disease, associated with the initiation of BETAIFERON therapy. Cases of cardiomyopathy have been reported: if this occurs and a relationship to BETAIFERON is suspected, treatment should be discontinued.

General disorders and administration site conditions:

Serious hypersensitivity reactions such as acute bronchospasm, anaphylaxis and urticaria may occur. If reactions are severe, BETAIFERON should be discontinued and appropriate medical intervention instituted. Other moderate to severe adverse experiences may require modifications of the BETAIFERON dosage regimen or discontinuation.

Injection site infection and injection site necrosis have been reported in patients using BETAIFERON. Injection site necrosis can be extensive and may involve muscle fascia as well as fat and therefore can result in scar formation. Occasionally debridement and, less often, skin grafting are required and healing may take up to 6 months.

If the patient experiences any break in the skin, which may be associated with swelling or drainage of fluid from the injection site, the patient should be advised to consult with their medical practitioner before continuing injections with BETAIFERON.

If the patient has multiple lesions, BETAIFERON should be discontinued until healing has occurred.

Patients with single lesions may continue on BETAIFERON, provided the necrosis is not too extensive, as some patients have experienced healing of injection site necrosis whilst on BETAIFERON.

To minimise the risk of injection site infection and injection site necrosis, patients should be advised to:

- use an aseptic injection technique,
- rotate the injection sites with each dose.

The procedure for the self-administration by the patient should be reviewed periodically especially if injection site reactions have occurred.

Thrombotic microangiopathy (TMA) and Hemolytic anaemia

• Cases of thrombotic microangiopathy, manifested as thrombotic thrombocytopenic purpura (TTP) or haemolytic uraemic syndrome (HUS) have been reported including fatal cases with BETAFERON. Events were reported at various time points during treatment and may occur several weeks to several years after starting treatment with BETAFERON. Early clinical features include thrombocytopenia, new onset hypertension and impaired renal function. Laboratory findings suggestive of TMA include decreased platelet counts, increased serum lactate dehydrogenase (LDH) and schistocytes (erythrocyte fragmentation) on a blood film. Therefore if clinical features of TMA are observed further testing of blood platelet levels, serum LDH, blood films and renal function is recommended. If TMA is diagnosed prompt treatment with plasma exchange is required and immediate discontinuation of BETAFERON is recommended.

Additionally, cases of hemolytic anemia (HA) not associated with TMA, including immune HA have been reported with BETAFERON. Life-threatening and fatal cases were reported. Cases have been reported several weeks to years after starting interferon beta products. If clinical symptoms and laboratory findings consistent with TMA and / or HA occur, and a relationship to BETAFERON is suspected, discontinue treatment and manage as clinically indicated.

Pulmonary Arterial Hypertension (PAH)

Cases of pulmonary arterial hypertension (PAH) have been reported with BETAFERON. Patients developing suspicious symptoms (e.g dyspnoea, fatigue accompanied by shortness of breath) should be assessed for PAH.

Other:

Caution should be exercised when administering BETAFERON to patients with myelosuppression, anaemia or thrombocytopenia; patients who develop neutropenia should be monitored closely for the development of fever or infection.

Renal function should be monitored carefully when such patients receive BETAFERON therapy.

Laboratory tests:

In addition to those laboratory tests normally required for monitoring patients with multiple sclerosis, complete blood and differential white blood cell counts, platelet counts, and blood chemistries, including liver function tests (e.g. AST (SGOT), ALT (SGPT) and gamma-GT), are recommended prior to initiation and at regular intervals following introduction of BETAFERON therapy, and then periodically thereafter in the absence of clinical symptoms.

Thyroid function tests are recommended regularly in patients with a history of thyroid dysfunction or as clinically indicated.

Patients with anaemia, thrombocytopenia, leukopenia (alone or in any combination) may require more intensive monitoring of complete blood cell counts, with differential and platelet counts.

4.5 Interaction with other medicinal products and other forms of interaction

No formal medicine interaction studies have been carried out with BETAFERON.

The effect of BETAFERON on medicine metabolism in multiple sclerosis patients is unknown. Corticosteroid or ACTH treatment of relapses for periods of up to 28 days has been well tolerated in patients receiving BETAFERON.

Due to the lack of clinical experience in multiple sclerosis patients, the use of BETAFERON together with immunomodulators other than corticosteroids or ACTH is not recommended.

Interferons such as BETAFERON have been reported to reduce the activity of hepatic cytochrome P450-dependent enzymes. Caution should be exercised when BETAFERON is administered in combination with medicines that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system for clearance, such as ketoconazole, itraconazole, macrolide antibiotics, etc. Caution should be exercised with any co-medication which has an effect on the haematopoietic system.

4.6 Fertility, pregnancy and lactation

Pregnancy:

It is not known whether BETAFERON can cause foetal harm when administered to a pregnant woman or can affect human reproductive capacity. Spontaneous abortions have been reported in subjects with multiple sclerosis using BETAFERON in controlled clinical trials. BETAFERON in studies with rhesus monkeys has been proven embryotoxic, causing a dose-related increase in the rate of abortions. Therefore, BETAFERON is contra-indicated during pregnancy and women of childbearing potential should take appropriate contraceptive measures. If the patient becomes pregnant or plans to become pregnant while taking BETAFERON, she should be informed of the potential hazard and it should be recommended to discontinue therapy.

If the patient plans to get pregnant, the benefits and possible risks of continuing BETAFERON therapy are recommended to be weighed. If the patient or becomes pregnant while taking Betaferon, the benefit and potential risks of continuing BETAFERON therapy, the individual disease severity and the potential detrimental effects that could occur if medication is stopped (e.g., on the individual disease activity) of drug discontinuation should be discussed with the patient.

Lactation:

It is not known whether interferon beta-1b is excreted in human milk. Because of the potential for serious adverse reactions to BETAFERON if infants are being breastfed, BETAFERON should be discontinued.

Fertility:

Reproduction studies with rhesus monkeys revealed maternal toxicity and an increased rate of abortions. No investigations on fertility have been conducted.

BETAFERON is contra-indicated in pregnancy and lactation.

4.7 Effects on ability to drive and use machines

This has not been investigated.

Central nervous system-related adverse events associated with the use of BETAFERON might influence the ability to drive and use machines in susceptible patients.

Contains mannitol and may have a laxative effect.

4.8 Undesirable effects

Flu-like symptom complex (fever, chills, headache, myalgia, arthralgia, malaise, or sweating) occur frequently. The incidence rate of the symptoms decreased over time.

Dose titration is recommended at the start of treatment in order to increase the tolerability to BETAIFERON. Flu-like symptoms may also be reduced by administration of non-steroidal anti-inflammatory medicines.

Injection site reactions (e.g. redness, swelling, discolouration, inflammation, pain, hypersensitivity, infection necrosis, and non-specific reactions) occur frequently after administration of BETAIFERON. The incidence rate of injection site reactions usually decreased over time. The incidence of injection site reactions may be reduced by the use of an autoinjector.

The most serious adverse reaction reported are thrombotic microangiopathy (TMA) and hemolytic anemia (HA).

The frequencies of adverse reactions (ARs) reported with BETAIFERON are summarised in the table below.

Frequencies are defined as very common ($\geq 1/10$) and common ($\geq 1/100$ to $< 1/10$).

The ADRs identified only during post-marketing surveillance, and for which a frequency could not be estimated, are listed under “not known”.

Table 2: Adverse reactions from clinical trials and from post-marketing experience.

System Organ Class	Very common	Common	Frequency not known:
Blood and lymphatic system disorders	Lymphocyte count decreased ($< 1500/\text{mm}^3$) ^x White blood cell count decreased (WBC) ($< 3000/\text{mm}^3$) ^x Absolute neutrophil count decreased (ANC) ($< 500/\text{mm}^3$) ^x	Lymphadenopathy	Anemia, Thrombocytopenia Leukopenia Thrombotic Microangiopathy** Hemolytic Anemia**
Immune system disorders			Anaphylactic reactions Capillary leak syndrome in preexisting monoclonal gammopathy
Endocrine disorders			Thyroid disorders, Hyperthyroidism, Hypothyroidism
Metabolism and nutrition disorders			Blood triglycerides increased, Anorexia, Weight decrease, Weight increase
Psychiatric disorders			Depression, Suicide attempt, Confusion, Anxiety, Emotional lability

Nervous system disorders	Headache Insomnia Incoordination		Convulsion, Dizziness
Cardiac disorders			Cardiomyopathy, Tachycardia, Palpitation
Vascular disorders		Hypertension	Vasodilatation
Respiratory, thoracic and mediastinal disorders		Dyspnoea	Bronchospasm
Gastrointestinal disorders	Abdominal pain		Nausea, Vomiting, Pancreatitis, Diarrhea
Hepatobiliary disorders	Alanine aminotransferase increased (ALT > 5 times baseline) ^x	Aspartate aminotransferase increased (AST > 5 times baseline) ^x	Blood bilirubin increased, Gamma-glutamyltransferase increased, Hepatic injury (including hepatitis), Hepatic failure
Skin and subcutaneous tissue disorders	Rash Skin disorder		Urticaria, Alopecia, Pruritus, Skin discoloration
Musculoskeletal, connective tissue and bone disorders	Myalgia Hypertonia		Arthralgia, Drug-induced lupus erythematosus
Renal and urinary disorders	Urinary urgency		
Reproductive system and breast disorders		Impotence ^b Metrorrhagia ^a	Menstrual disorder, Menorrhagia
General disorders and administration site conditions	Injection site reaction (various kinds ^o) Flu-like symptoms (complex [§]) Pain Fever Chills Peripheral oedema Asthenia	Injection site necrosis Chest pain Malaise	Sweating
<p>** life-threatening and/or fatal cases have been reported.</p> <p>^x laboratory abnormality</p> <p>^a pre-menopausal women</p> <p>^b Men</p> <p>^o "Injection site reaction (various kinds)" comprises all adverse events occurring at the injection site (except injection site necrosis), i.e. the following terms: injection site atrophy, injection site oedema, injection site haemorrhage, injection site hypersensitivity, injection site infection, injection site inflammation, injection site mass, injection site pain, and injection site reaction.</p> <p>[§] "Flu-like symptom complex" denotes flu syndrome and/or a combination of at least two AEs from fever, chills, myalgia, malaise, sweating.</p>			

Pulmonary arterial hypertension

Cases of pulmonary arterial hypertension (PAH) have been reported with BETA FERON. Events were reported at various time points including up to several years after starting treatment with BETA FERON.

Investigations/immunogenicity:

There is a potential for immunogenicity. Serum samples in controlled clinical trials were collected every 3 months (in the study of patients with a single clinical event suggestive of multiple sclerosis every 6 months) for monitoring of development of antibodies to BETAFERON.

In the different controlled clinical trials, between 23 % and 41 % of the patients developed serum interferon beta-1b neutralising activity confirmed by at least two consecutive positive titers; of these patients, between 43 % to 55 % converted to a stable antibody negative status (based on two consecutive negative titers) during the subsequent observational period of the respective study.

In the study of patients with a single clinical event suggestive of multiple sclerosis, neutralising activity measured every 6 months was observed at least once in 32 % (89) of the BETAFERON patients treated early; of these 60 % (53) returned to negative status based on the latest available assessment within the 5 year period. Within the study period of 5 years the development of neutralising activity was not associated with a reduction in clinical efficacy [with regard to time to clinically definite multiple sclerosis (CDMS), time to confirmed Expanded Disability Status (EDSS) scale saying now don't look at progression and relapse rate].

No consistent attenuating effects on clinical outcomes have been demonstrated related to the presence of neutralising antibodies, across studies, endpoints, different statistical approaches and varying definitions of neutralising antibody positive status. Adverse events have not been associated with the development of neutralising activity.

The decision to continue or discontinue treatment should be based on all aspects of the patient's disease status rather than on neutralising activity status alone.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare providers are asked to report any suspected adverse reactions to SAHPRA via the "6.04 Adverse Drug Reactions Reporting Form", found online under SAHPRA's publications: <https://www.sahpra.org.za/Publications/Index/8>

4.9 Overdose

Symptoms are expected to be as the side effects.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Cytokines, Interferons,
ATC Code: L03 AB 08

Mechanism of action

Interferons belong to the family of cytokines, which are naturally occurring proteins. Interferons have molecular weights ranging from 15,000 to 21,000 Daltons. Three major classes of interferons have been identified: alpha, beta, and gamma. Interferon alpha, interferon beta, and interferon gamma have overlapping yet distinct biologic activities. The activities of interferon beta-1b are species-restricted and therefore, the most pertinent pharmacological information on interferon beta-1b is derived from studies of human cells in culture or in human *in vivo* studies.

Interferon beta-1b has been shown to possess both antiviral and immunoregulatory activities. The mechanisms by which interferon beta-1b exerts its actions in multiple sclerosis are not clearly understood. However, it is known that the biologic response-modifying properties of interferon beta-1b are mediated

through its interactions with specific cell receptors found on the surface of human cells. The binding of interferon beta-1b to these receptors induces the expression of a number of gene products that are believed to be the mediators of the biological actions of interferon beta-1b. A number of these products have been measured in the serum and cellular fractions of blood collected from patients treated with interferon beta-1b.

No separate investigations were performed regarding the influence of BETAIFERON on the cardiovascular system, respiratory system and the function of endocrine organs.

5.2 Pharmacokinetic properties

Serum concentrations after subcutaneous administration of 0,25 mg (8 million IU) cannot be detected or are low and maximum serum levels of about 40 IU/ml were found 1 to 8 hours after subcutaneous injection of 500 microgram (16.0 million IU) interferon beta-1b. From various studies mean clearance rates and half-lives of disposition phases from serum were estimated to be at most $30 \text{ ml} \cdot \text{min}^{-1} \cdot \text{kg}^{-1}$ and 5 hours, respectively.

Every other day drug injections do not lead to drug accumulation and pharmacokinetics do not seem to change during therapy.

5.3 Preclinical safety data

In animals transitory hyperthermia was observed, as well as a significant rise in lymphocytes and a significant decrease in thrombocytes and segmented neutrophils.

Reproduction studies with rhesus monkeys revealed maternal toxicity and an increased rate of abortion, resulting in prenatal mortality.

No investigations on fertility have been conducted.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients:

Vial (with powder for solution for injection):

Human albumin

Mannitol

Solvent (sodium chloride solution 5.4 mg/ml (0.54% w/v)):

Sodium chloride

Water for injection

6.2 Incompatibilities

In the absence of compatibility studies, BETAIFERON should not be mixed with other medicinal products.

Treatment should start as soon as the definite diagnosis of relapsing-remitting multiple sclerosis has been made and the patient has had at least two exacerbations. The treating physician should inform the patient of the possible risk and benefit of a treatment with BETAIFERON and decide with him/her whether he/she would be willing to accept possible side effects and inconveniences that might be related to the treatment with BETAIFERON.

6.3 Shelf life

2 years.

After reconstitution, store at 2 to 8 °C for up to 3 hours.

6.4 Special precautions for storage

Store at or below 30°C.

6.5 Nature and contents of container

BETAFERON:

Vial (with powder for solution for injection):

One 3 ml clear vial (type I glass) with a butyl rubber stopper (type I) and aluminium overseal containing a white lyophilised cake and

DILUENT FOR BETAFERON:

Prefilled syringes (no vial adapter):

One 1,2 ml prefilled glass syringe containing 1,2 ml of a clear colourless solvent.

Prefilled syringes with vial adapter and attached needle:

One 2,25 ml prefilled glass syringe containing 1,2 ml of a clear colourless solvent.

Pack sizes

Viols:

One pack containing 15 vials of BETAFERON and 15 vials of DILUENT FOR BETAFERON.

Prefilled syringes (no vial adapter):

One pack containing 15 vials of BETAFERON and 15 prefilled syringes of DILUENT FOR BETAFERON.

Prefilled syringes with vial adapter and attached needle:

One outer pack containing 5 or 15 single packs. Each single pack consists of 1 vial with BETAFERON powder, 1 prefilled syringe with DILUENT FOR BETAFERON, 1 vial adapter with needle and 2 alcohol wipes.

6.6 Special precautions for disposal and other handling

Reconstitution / Administration

After reconstitution, draw 1.0 mL from the vial into the syringe for the administration of 250 micrograms BETAFERON.

For dose titration at the start of treatment draw the respective volume as given in section '4.2 Posology and method of administration.'

Discard any unused solution for injection.

Inspection prior to use

Do not use cracked vials. Inspect the reconstituted product visually before use. Discard the product before use if it contains particulate matter or is discolored.

7. HOLDER OF CERTIFICATE OF REGISTRATION

Bayer (Pty) Ltd
27 Wrench Road
ISANDO

1609, Reg. No.: 1968/011192/07

8. REGISTRATION NUMBER

BETAFERON: 30/34/0185

DILUENT FOR BETAFERON: 30/34/0186

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

08 October 1996

10. DATE OF REVISION OF THE TEXT

19 December 2023